8-K: Aimei Health Technology Receives Nasdaq Delisting Warning

Aimei Health Technology Co., Ltd. has received a notice from Nasdaq for failing to file its annual report on time, risking delisting if compliance is not regained.

Summary

• Aimei Health Technology Co., Ltd. received a notice from Nasdaq on April 17, 2026, stating it is not in compliance with listing rules due to the delayed filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• The Annual Report was originally due on March 31, 2026.
• The company filed a Notification of Late Filing on Form 12b-25 with the SEC on April 1, 2026.
• This notice does not immediately affect the trading of the company's securities on Nasdaq.
• However, the company must regain compliance within 60 days of the notice date (April 17, 2026) by filing the Annual Report or submitting an acceptable plan to Nasdaq.
• If a plan is accepted, the company may have up to 180 days from the original due date to regain compliance.
• The company is actively working to complete and file the Annual Report and expects to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the immediate risk of delisting from Nasdaq, despite management's assurances of working towards compliance.

Positives

• The notice from Nasdaq has no immediate effect on the listing or trading of the company's securities.
• The company is working diligently to complete and file the Annual Report and expects to regain compliance.

Negatives

• The company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• Failure to regain compliance could lead to the delisting of the company's securities from Nasdaq.

Risks

• Potential delisting from The Nasdaq Stock Market LLC if the company fails to regain compliance with listing rules.
• The company may not be able to file its Annual Report within the specified timelines.
• Nasdaq may not accept the company's plan to regain compliance, leading to further appeals or delisting.
• Business, economic, competitive, regulatory, and other inherent risks and uncertainties that are difficult to predict and beyond the company's control.

Future Outlook

The company is working diligently to complete and file the Annual Report and expects to regain compliance with the Nasdaq Listing Rule.

Management Comments

• The Company is working diligently to complete and file the Annual Report and expects to regain compliance with the Listing Rule.

Industry Context

StockSavvy.ai notes that timely filing of financial reports is a fundamental requirement for listed companies. Delays can signal internal control weaknesses or operational challenges, often leading to increased investor scrutiny and potential stock price volatility.

Stakeholder Impact

• Shareholders: Potential for increased volatility and risk of delisting, which could impact liquidity and investment value.
• Creditors: Potential concerns about the company's financial reporting and operational stability.
• Employees: Uncertainty regarding the company's future listing status and operational continuity.

Next Steps

• File the Annual Report on Form 10-K with the SEC.
• Regain compliance with Nasdaq Listing Rule 5250(c)(1).
• Submit a plan to Nasdaq to regain compliance if the Annual Report cannot be filed within the initial 60-day period.
• Potentially appeal a Nasdaq hearings panel decision if a submitted plan is not accepted.

Key Dates

Recommendation

The company is facing a significant compliance issue with Nasdaq, creating uncertainty and risk. However, management is actively working to resolve the situation and expects to regain compliance. A 'hold' recommendation reflects the balance between the immediate risk and the potential for resolution, pending the timely filing of the annual report and Nasdaq's decision on compliance.

Keywords

Nasdaq, Delisting, Form 8-K, Annual Report, Compliance, SEC Filing, Aimei Health Technology, Late Filing